The House of Representatives has approved a revised version of the 21st Century Cures Act, a comprehensive $6.3 billion health care reform measure that would fund the National Cancer Moonshot Initiative and amend FDA standards for regulating drugs and devices.
In an unusual move, the National Cancer Advisory Board fired off a letter urging Congress to authorize additional “moonshot” funds, and—just as importantly—to place these new funds in the NCI budget.
Amgen announced that a phase III study evaluating XGEVA (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority (hazard ratio = 0.98, 95 percent CI, 0.85 - 1.14) in delaying the time to first on-study skeletal-related event in patients with multiple myeloma.
Sixty percent of men whose testicular cancer returned were cured with high-dose chemotherapy and a stem cell transplant, according to research published by Indiana University researchers.
Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a phase III clinical trial of Axumin (fluciclovine F 18) injection.
OncoGenex Pharmaceuticals Inc. announced today positive survival results from the final analysis of the phase II Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy.
The College of American Pathologists, the American Society for Clinical Pathology, and the American Society of Clinical Oncology released an evidence-based clinical practice guideline on human epidermal growth factor receptor 2 testing for patients with gastroesophageal cancers.
NCI CTEP approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Nektar Therapeutics announced that new phase I clinical data for Nektar's lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting.
